Sana Biotechnology, Inc. (SANA)
2.89
0.00 (0.00%)
USD |
NASDAQ |
Oct 02, 16:00
2.90
+0.01
(+0.35%)
After-Hours: 20:00
Sana Biotechnology Enterprise Value : 774.05M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 774.05M |
| October 01, 2026 | 774.05M |
| September 30, 2026 | 781.53M |
| September 29, 2026 | 780.03M |
| September 28, 2026 | 786.02M |
| September 25, 2026 | 790.51M |
| September 24, 2026 | 795.00M |
| September 23, 2026 | 830.92M |
| September 22, 2026 | 905.74M |
| September 21, 2026 | 836.90M |
| September 18, 2026 | 836.90M |
| September 17, 2026 | 836.90M |
| September 16, 2026 | 783.03M |
| September 15, 2026 | 854.86M |
| September 14, 2026 | 866.83M |
| September 11, 2026 | 845.88M |
| September 10, 2026 | 833.91M |
| September 09, 2026 | 857.85M |
| September 08, 2026 | 941.66M |
| September 04, 2026 | 1.061B |
| September 03, 2026 | 1.082B |
| September 02, 2026 | 1.073B |
| September 01, 2026 | 1.055B |
| August 31, 2026 | 1.067B |
| August 28, 2026 | 1.085B |
| Date | Value |
|---|---|
| August 27, 2026 | 1.133B |
| August 26, 2026 | 1.154B |
| August 25, 2026 | 1.136B |
| August 24, 2026 | 1.040B |
| August 21, 2026 | 1.079B |
| August 20, 2026 | 1.028B |
| August 19, 2026 | 1.136B |
| August 18, 2026 | 995.53M |
| August 17, 2026 | 1.011B |
| August 14, 2026 | 971.59M |
| August 13, 2026 | 1.008B |
| August 12, 2026 | 1.037B |
| August 11, 2026 | 1.043B |
| August 10, 2026 | 989.55M |
| August 07, 2026 | 962.61M |
| August 06, 2026 | 929.69M |
| August 05, 2026 | 959.62M |
| August 04, 2026 | 926.69M |
| August 03, 2026 | 860.85M |
| July 31, 2026 | 845.88M |
| July 30, 2026 | 881.80M |
| July 29, 2026 | 857.85M |
| July 28, 2026 | 893.77M |
| July 27, 2026 | 890.78M |
| July 24, 2026 | 860.85M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.352B |
| Twist Bioscience Corp. | 11.75B |
| Beam Therapeutics, Inc. | 1.624B |
| Prime Medicine, Inc. | 556.00M |
| Revolution Medicines, Inc. | 41.52B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -63.64M |
| Total Expenses (Quarterly) | 63.64M |
| EPS Diluted (Quarterly) | -0.2152 |
| Earnings Yield | -26.32% |
| Normalized Earnings Yield | -23.48 |